Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 497

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 497
---
 |
| Net loss                                                                                                      |     |                                               | (7,178,333 | )     |     |                  | (1,980,810 | )    |     |             | 5,087,293 |   |     |       |     |           | (4,071,850 | ) |
| Defined pension plan adjustments                                                                              |     |                                               |     (7,000 | )     |     |                  |    266,924 |      |     |             |         — |   |     |       |     |           |    259,924 |   |
| Effect of exchange rate changes                                                                               |     |                                               |    (92,000 | )     |     |                  |          — |      |     |             |         — |   |     |       |     |           |    (92,000 | ) |
| Total comprehensive loss                                                                                      |     | $                                             | (7,277,333 | )     |     | $                | (1,713,886 | )    |     | $           | 5,087,293 |   |     |       |     | $         | (3,903,926 | ) |

____________ (i)This gives effect to the reverse stock split of 1 -for-40as of September 27, 2024. (ii)Adjusted retroactively due to (A) the rights issue under the shelf offering by way of rights published by the Company in 2022 in such a way that each shareholder who held 100 Shares would be entitled to purchase 1 rights unit, with 1 rights unit consisted of 32 Shares, and the total price of each rights unit was USD $10 and the total number of rights units offered was up to 14,623,392 rights units, and (B) the reverse share split conducted by Kadimastem in March 2024, at a 10 -for-1ratio. The accompanying notes are an integral part of these unaudited pro forma condensed combined financial statements.

271 Kadimastem Ltd. & NLS Pharmaceutics Ltd.
Notes to accompanying Financial Statements 1.Description of the Proposed Transaction and Basis of Presentation NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (“NLS”), a biopharmaceutical company, and Kadimastem Ltd. (TASE: KDST.TA”) (“Kadimastem”), a clinical -stagecell therapy company developing and manufacturing “off -